Literature DB >> 22207718

The RANKL distal control region is required for the increase in RANKL expression, but not the bone loss, associated with hyperparathyroidism or lactation in adult mice.

Melda Onal1, Carlo Galli, Qiang Fu, Jinhu Xiong, Robert S Weinstein, Stavros C Manolagas, Charles A O'Brien.   

Abstract

Osteoclast-mediated bone resorption plays an essential role in calcium homeostasis and lactation. The cytokine receptor activator of nuclear factor κB ligand (RANKL) is one of a number of factors that controls the production, survival, and activity of osteoclasts. Calciotropic hormones, such as PTH, control RANKL transcription in part via an enhancer known as the distal control region (DCR), and mice lacking this enhancer have fewer osteoclasts under normal physiological conditions. Here, we have addressed the role of the DCR in situations in which activation of the PTH receptor is thought to stimulate bone resorption via elevation of RANKL expression. Dietary calcium deficiency stimulated RANKL expression in the bone of young (1 month old) wild-type, but not DCR knockout (KO), mice. Consistent with this, the cancellous bone loss and the increase in osteoclasts caused by dietary calcium deficiency were blunted in young KO mice. DCR deletion also prevented the increase in RANKL expression caused by dietary calcium deficiency in 6-month-old mice. However, the diet-induced bone loss was similar in wild-type and KO mice at this age. The increase in RANKL expression caused by lactation was also blunted in DCR KO mice, but lactation-induced bone loss was similar in both genotypes. These results demonstrate that, even though the DCR is required for the increase in RANKL expression associated with hyperparathyroidism or lactation, this increase is not required for the bone loss caused by these conditions in adult mice, suggesting that changes in other factors, such as osteoprotegerin or estrogen levels, play a dominant role.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22207718      PMCID: PMC3275157          DOI: 10.1210/me.2011-1149

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  30 in total

Review 1.  Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis.

Authors:  S C Manolagas
Journal:  Endocr Rev       Date:  2000-04       Impact factor: 19.871

Review 2.  Genetic regulation of osteoclast development and function.

Authors:  Steven L Teitelbaum; F Patrick Ross
Journal:  Nat Rev Genet       Date:  2003-08       Impact factor: 53.242

3.  Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Authors:  D L Lacey; E Timms; H L Tan; M J Kelley; C R Dunstan; T Burgess; R Elliott; A Colombero; G Elliott; S Scully; H Hsu; J Sullivan; N Hawkins; E Davy; C Capparelli; A Eli; Y X Qian; S Kaufman; I Sarosi; V Shalhoub; G Senaldi; J Guo; J Delaney; W J Boyle
Journal:  Cell       Date:  1998-04-17       Impact factor: 41.582

4.  Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee.

Authors:  A M Parfitt; M K Drezner; F H Glorieux; J A Kanis; H Malluche; P J Meunier; S M Ott; R R Recker
Journal:  J Bone Miner Res       Date:  1987-12       Impact factor: 6.741

Review 5.  Bone and plasma calcium homeostasis.

Authors:  A M Parfitt
Journal:  Bone       Date:  1987       Impact factor: 4.398

6.  Osteoprotegerin reduces the serum level of receptor activator of NF-kappaB ligand derived from osteoblasts.

Authors:  Yuko Nakamichi; Nobuyuki Udagawa; Yasuhiro Kobayashi; Midrori Nakamura; Yohei Yamamoto; Teruhito Yamashita; Toshihide Mizoguchi; Masahiro Sato; Makio Mogi; Josef M Penninger; Naoyuki Takahashi
Journal:  J Immunol       Date:  2007-01-01       Impact factor: 5.422

7.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

Authors:  H Yasuda; N Shima; N Nakagawa; K Yamaguchi; M Kinosaki; S Mochizuki; A Tomoyasu; K Yano; M Goto; A Murakami; E Tsuda; T Morinaga; K Higashio; N Udagawa; N Takahashi; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

8.  Low estrogen and high parathyroid hormone-related peptide levels contribute to accelerated bone resorption and bone loss in lactating mice.

Authors:  Joshua N VanHouten; John J Wysolmerski
Journal:  Endocrinology       Date:  2003-09-18       Impact factor: 4.736

9.  Skeletal abnormalities in Pth-null mice are influenced by dietary calcium.

Authors:  Dengshun Miao; Bin He; Beate Lanske; Xiu-Ying Bai; Xin-Kang Tong; Geoffrey N Hendy; David Goltzman; Andrew C Karaplis
Journal:  Endocrinology       Date:  2003-12-30       Impact factor: 4.736

10.  Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein.

Authors:  Qiang Fu; Robert L Jilka; Stavros C Manolagas; Charles A O'Brien
Journal:  J Biol Chem       Date:  2002-10-02       Impact factor: 5.157

View more
  14 in total

1.  The osteoblast to osteocyte transition: epigenetic changes and response to the vitamin D3 hormone.

Authors:  Hillary C St John; Kathleen A Bishop; Mark B Meyer; Nancy A Benkusky; Ning Leng; Christina Kendziorski; Lynda F Bonewald; J Wesley Pike
Journal:  Mol Endocrinol       Date:  2014-05-30

Review 2.  The Role of Osteocytes in Age-Related Bone Loss.

Authors:  Robert L Jilka; Charles A O'Brien
Journal:  Curr Osteoporos Rep       Date:  2016-02       Impact factor: 5.096

Review 3.  Osteocyte control of osteoclastogenesis.

Authors:  Charles A O'Brien; Tomoki Nakashima; Hiroshi Takayanagi
Journal:  Bone       Date:  2012-08-23       Impact factor: 4.398

4.  A DNA segment spanning the mouse Tnfsf11 transcription unit and its upstream regulatory domain rescues the pleiotropic biologic phenotype of the RANKL null mouse.

Authors:  Melda Onal; Kathleen A Bishop; Hillary C St John; Allison L Danielson; Erin M Riley; Marilina Piemontese; Jinhu Xiong; Joseph J Goellner; Charles A O'Brien; J Wesley Pike
Journal:  J Bone Miner Res       Date:  2015-05       Impact factor: 6.741

5.  OPG Treatment Prevents Bone Loss During Lactation But Does Not Affect Milk Production or Maternal Calcium Metabolism.

Authors:  Laleh Ardeshirpour; Cristina Dumitru; Pamela Dann; John Sterpka; Joshua VanHouten; Wonnam Kim; Paul Kostenuik; John Wysolmerski
Journal:  Endocrinology       Date:  2015-05-11       Impact factor: 4.736

6.  Deletion of a Distal RANKL Gene Enhancer Delays Progression of Atherosclerotic Plaque Calcification in Hypercholesterolemic Mice.

Authors:  Sohel Shamsuzzaman; Melda Onal; Hillary C St John; J Wesley Pike
Journal:  J Cell Biochem       Date:  2017-05-30       Impact factor: 4.429

7.  Osteocyte-derived RANKL is a critical mediator of the increased bone resorption caused by dietary calcium deficiency.

Authors:  Jinhu Xiong; Marilina Piemontese; Jeff D Thostenson; Robert S Weinstein; Stavros C Manolagas; Charles A O'Brien
Journal:  Bone       Date:  2014-06-14       Impact factor: 4.398

8.  Deletion of the Distal Tnfsf11 RL-D2 Enhancer That Contributes to PTH-Mediated RANKL Expression in Osteoblast Lineage Cells Results in a High Bone Mass Phenotype in Mice.

Authors:  Melda Onal; Hillary C St John; Allison L Danielson; J Wesley Pike
Journal:  J Bone Miner Res       Date:  2016-02       Impact factor: 6.741

9.  Unique Distal Enhancers Linked to the Mouse Tnfsf11 Gene Direct Tissue-Specific and Inflammation-Induced Expression of RANKL.

Authors:  M Onal; H C St John; A L Danielson; J W Markert; E M Riley; J W Pike
Journal:  Endocrinology       Date:  2015-12-08       Impact factor: 4.736

Review 10.  Could use of Selective Serotonin Reuptake Inhibitors During Lactation Cause Persistent Effects on Maternal Bone?

Authors:  Samantha R Weaver; Laura L Hernandez
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-03-30       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.